TCRR - TCR2 Therapeutics Announces Positive Results from Phase ½ Trial of GAVO-CEL to Treat Solid Tumors

TCR2 Therapeutics Inc. (NASDAQ: TCRR) has announced positive interim results from its Phase 1 portion of the gavo-cel Phase ½ clinical trial for mesothelin-expressing solid tumors.  As of June 30, 2021, 17 patients have received a single gavo-cel infusion in the phase 1 clinical trial.  “The interim gavo-cel data reported today showed continued clinical benefit and a manageable safety profile in a population of patients that previously achieved minimal or no improvement due to the advanced and aggressive state of their cancer,” said principal investigator David Hong, M.D., deputy chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. “Patients with treatment refractory cancer have very limited treatment options and will often need hospice and supportive care. We are encouraged by the early survival data from gavo-cel in patients previously treated with checkpoint inhibitors and other therapies.”

“Our ambition with gavo-cel from the start was to redefine treatment for solid tumors with cell therapies. We are excited to present data demonstrating clinical activity in all three mesothelin-expressing solid tumors treated to date and tumor regression in a majority of patients who are treatment refractory after numerous lines of therapy. We are very encouraged by the progression free survival and overall survival observed among patients with refractory mesothelioma treated so far with gavo-cel in the Phase 1 trial,” said Alfonso Quintás-Cardama, M.D., Chief Medical Officer of TCR2 Therapeutics. “Based on these data and the most recent patient experiencing a very mild safety profile at a cell dose of 3×108/m2, we believe the identification of the RP2D is close at hand. As we approach the Phase 2 expansion phase, our focus will shift to further optimizing outcomes for patients by studying combinations with immune checkpoint inhibitors, allowing gavo-cel re-treatment and evaluating different mesothelin expression thresholds.”

The post TCR2 Therapeutics Announces Positive Results from Phase ½ Trial of GAVO-CEL to Treat Solid Tumors first appeared on Financial Buzz .

For further details see: